Pharma Two B Ltd.

pharma2b.com

High-Tech Company

Ceased to Operate Q1/2025

TECH VERTICALS

Life Sciences, MedTech, Pharmaceuticals, Therapeutics

General Data

Sector	Biomed
Company Stage:	R&D
Established	2007
Number of Employees	10
Reg. Number:	abCDe

DESCRIPTION

Pharma Two B develops clinically differentiated and value-added products, based on approved drugs. They focus on Combination Products of two or more drugs with complementary and synergistic effects, providing high clinical value and shorter regulatory pathways (US 505b2 approach). The company develops products in two therapeutic areas with great unmet needs - Parkinson's disease (PD) and Cancer.
All of Pharma Two B candidates are known drugs. The company efforts are primarily devoted to pharmacologically characterizing and optimizing synergistic combinations with improved therapeutic effect. In addition, Pharma Two B provides optimized formulations which enhance the pharmacological activity and provide additional value to the new products IP.

TECHNOLOGY

Pharma Two B offers a complete package of solutions for fast and efficient development of combination products and complex generics, from basic pharmacology to final dosage form, either standard or more complicated Drug-Delivery-System (DDS), supported by their activities in:

1. Search for new indications/combinations
2. Model design and pharmacological evaluation of synergistic effects
3. New formulations
4. DDS solutions (mainly oral) activity and provide additional value to the new products IP.

Products and Phases

Product	Phase
P2B 001	Phase III
P2B001 is a low dose, sustained release combination of pramipexole and resagiline. P2B001 is dosed once daily with no titration. Data from P2B001 phase II clinical trial implies that it may provide significant therapeutic effects comparable to those published for higher doses of the individual components, with favorable safety profile. Monoamine oxidase-B inhibitors or dopamine agonists are approved treatments for early PD patients are associated with efficacy or safety limitations. P2B001, contains low doses of the dopamine agonists pramipexole, and the monoamine oxidase-B inhibitor rasagiline that have complementary mechanisms of action. Preclinical studies demonstrate that the combination provides synergistic effects, which are further enhanced if both agents are given in slow release. The synergy between the combination components implies that lower doses maybe used without compromising the therapeutic effect, while maintaining manageable safety profile, due to the decreased drug amounts.
P2B001EA for Early Stage PD Patients	Phase III
P2B001 is developed for treatment of early stage or newly diagnosed patients. Because it contains two of the most prescribed drugs currently given to this patient population, but contains lower doses and sustained release delivery profile. In light of the efficacy and safety data in its phase II clinical trial, we are further evaluating whether P2B001 may offer a better treatment option than either of its individual components in their current dosage form P2B001 also offers significant convenience of use, being a once daily treatment that needs no titration.
P2B001AD for Advanced PD Patients	Phase III
Pharma Two B is developing P2B001 also for the treatment of more advanced Parkinson’s disease patients who are using Levodopa. Levodopa is an effective drug however, it is associated with the development of motor complications such as dyskinesia, and with efficacy fluctuations leading to “on/”off” time. This limitations are associated with increasing doses. Using P2B001 as add-on to low dose levodopa, may help Keeping Levodopa dose as low as possible for as long as possible, without compromising efficacy. A phase III clinical trial evaluating the advantage of P2B001 as add-on to Levodopa is planned in the near future.

	TARGET MARKETS
	Patients suffering from Parkinson's disease (PD) and Cancer.

	BUSINESS MODEL
	B2C

REMARKS

Date	Remark
22/07/2024	Pharma Two B announced plans to go public via merger with Hepion Pharmaceuticals, Inc. and concurrent $11.5m private placement. 12/2024: The merger agreement has been terminated and the merger will no longer take place.

CONTACT INFO

Expand / Collapse All

Main Address: Rehovot, Israel

Address	3 Pekeris St., Weizmann Science Park
City	Rehovot
Country	Israel
Zip	7670203

Contact Person	abC Defghij
Contact E-Mail	abC Defghij
Company E-mail	abC Defghij
Telephone	abC Defghij
Fax	abC Defghij

	MANAGEMENT

Key Executive

Name	Title	Previous Position
Dr. Itschak Lamensdorf	Co-Founder	QBI (Manager of the Neurobiology Unit)
Mr. Ehud Marom	Co-Founder
Dr. Yoram Sela	Co-Founder	LycoRed (VP, R&D)

	BOARD

Board

Member	Title	Affiliation
abC Defghij	Board Member	Chairman & CEO, Mapi Pharma
abC Defghij	Board Member	Co-Founder, Crossroad Fund FCP-FIS (Generali)
abC Defghij	Board Member	Managing Partner & Co-Founder, Israel Biotech Fund (IBF)
abC Defghij	Board Member	Founder, JK&B
abC Defghij	Board Member	VP Corporate Development, Mapi Pharma

	FINANCIAL ROUNDS

Total Capital Raised
abCDe

Financial Rounds

Numbers of Investors

Expand / Collapse All

Round

Date

Stage

Amount

Valuation

Second Round

Feb. 27, 2017

R&D

abCDe

* New investor

Investor	Type	Amount	Remarks
abC Defghij	Venture Capital Fund	abCDe
abC Defghij	Venture Capital Fund	abCDe
abC Defghij	Venture Capital Fund	abCDe	Led the round
abC Defghij	Venture Capital Fund	abCDe
abC Defghij	Investment Company	abCDe

First Round

Oct. 23, 2012

R&D

abCDe

* New investor

Investor	Type	Amount	Remarks
abC Defghij	Venture Capital Fund	abCDe
abC Defghij	Venture Capital Fund	abCDe	Led the round
abC Defghij	Private Investor	abCDe

Seed

Oct. 01, 2008

Seed

abCDe

	R&D Grants

Expand / Collapse All

Round

Date

Stage

Amount

Remarks

R&D Grant

Jun. 01, 2019

abCDe

* New investor

Investor	Type	Amount	Remarks
abC Defghij	Government Agency	abCDe

R&D Grant

Jun. 01, 2018

R&D

abCDe

* New investor

Investor	Type	Amount	Remarks
abC Defghij*	Government Agency	abCDe

Last Updated:	abCDe
IVC Number:	abCDe